tradingkey.logo

enVVeno Medical Corp

NVNO
9.900USD
-0.520-4.99%
收盘 02/09, 16:00美东报价延迟15分钟
4.46M总市值
亏损市盈率 TTM

enVVeno Medical Corp

9.900
-0.520-4.99%

关于 enVVeno Medical Corp 公司

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

enVVeno Medical Corp简介

公司代码NVNO
公司名称enVVeno Medical Corp
上市日期May 31, 2018
CEOBerman (Robert A)
员工数量37
证券类型Ordinary Share
年结日May 31
公司地址70 Doppler
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92618
电话19492612900
网址https://envveno.com/
公司代码NVNO
上市日期May 31, 2018
CEOBerman (Robert A)

enVVeno Medical Corp公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 2月7日 周六
更新时间: 2月7日 周六
持股股东
股东类型
持股股东
持股股东
占比
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
其他
71.72%
持股股东
持股股东
占比
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
其他
71.72%
股东类型
持股股东
占比
Individual Investor
9.48%
Investment Advisor
8.80%
Private Equity
7.67%
Hedge Fund
7.22%
Investment Advisor/Hedge Fund
1.68%
Research Firm
1.18%
Venture Capital
0.18%
其他
63.79%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
80
175.24K
26.73%
-63.76K
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Satterfield (Thomas A Jr)
1.82M
9.02%
+1.82M
--
Nov 14, 2025
Perceptive Advisors LLC
1.76M
8.7%
+474.07K
+36.89%
Sep 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
6.72%
+500.00K
+58.19%
Sep 30, 2025
CM Management, LLC
600.00K
2.97%
+600.00K
--
Sep 30, 2025
The Vanguard Group, Inc.
861.19K
4.26%
+162.85K
+23.32%
Sep 30, 2025
Berman (Robert Andrew)
222.24K
1.1%
+200.00K
+899.44%
Oct 17, 2025
Geode Capital Management, L.L.C.
201.24K
1%
+1.74K
+0.87%
Sep 30, 2025
J.P. Morgan Securities LLC
182.32K
0.9%
+22.00
+0.01%
Sep 30, 2025
Susquehanna International Group, LLP
154.47K
0.76%
+154.47K
--
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
公告日期
除权除息日
类型
比率
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
KeyAI